New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
07:17 EDTHZNPHorizon Pharma acquisition to be significantly accretive, says Stifel
After Horizon Pharma announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon's deal activity is favorable overall as it increases product diversity and leverages the company's promotional activities. Stifel keeps an $18 price target and Buy rating on the shares.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2014
07:32 EDTHZNPHorizon Pharma, POZEN announce USPTO Notice of Allowance for VIMOVO
Subscribe for More Information
August 8, 2014
10:34 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
07:35 EDTHZNPHorizon announces S-4 registration statement for Vidara declared effective
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use